COVID-19 vaccine associated demyelination & its association with MOG antibody

•Report of twenty nine cases of CNS demyelination with close temporal association to COVID-19 vaccination.•Clinical presentation is heterogenous, including myelitis, optic neuritis, ADEM, brainstem demyelination and multiaxial involvement.•Most prevalent antibody in postvaccinial cases is the antibody against MOG antigen.•As compared to the controls, postvaccinial demyelination cases have significantly higher encephalopathy features, CSF pleocytosis and raised CSF protein. ChAdOx1-S (Covishield™/Vaxzervria, AstraZeneca) and BBV152 (Covaxin) SARS-CoV-2 vaccines are proven to be safe and effective, but rare complications have been reported. To describe reports of central nervous system (CNS) demyelination following ChAdOx1-S and BBV152 vaccinations. We report 29 (17 female; mean 38 years) cases of CNS demyelination; twenty-seven occurred in temporal association with ChAdOx1-S vaccine; two in association with BBV152 vaccine. Eleven patients had presentation with myelitis, six patients developed optic neuritis, five had acute demyelinating encephalomyelitis, three presented with brainstem demyelination, and four had multiaxial involvement. Myelin oligodendrocyte glycoprotein (MOG) antibodies were positive in ten patients. One patient with ADEM and tumefactive demyelinating lesions died after a prolonged intensive care unit stay and superimposed infection. As compared to the control group (87); the postvaccinial cases were found to have a significantly higher mean age, presence of encephalopathy (p value:0.0007), CSF pleocytosis (p value: 0.0094) and raised CSF protein (p value: 0.0062). It is difficult to establish a causal relationship between vaccination and neurological adverse events such as demyelination. The temporal association with the vaccination and the presence of MOG antibodies raises the possibility of an immunogenic process triggered by the vaccine in susceptible individuals.